Kevetrin, with the CAS number 500863-50-3, is a small molecule compound that has garnered attention in the field of cancer research. It is primarily known for its potential as an anti-cancer agent, particularly due to its ability to activate the p53 tumor suppressor pathway. The p53 protein plays a crucial role in regulating the cell cycle and preventing tumor formation, making Kevetrin a candidate for therapeutic applications in various malignancies. The compound is characterized by its unique chemical structure, which facilitates its interaction with cellular mechanisms involved in tumor suppression. In preclinical studies, Kevetrin has demonstrated the ability to induce apoptosis in cancer cells and inhibit tumor growth, highlighting its potential efficacy. Additionally, its pharmacological profile suggests a favorable safety margin, although further clinical trials are necessary to fully establish its therapeutic potential and safety in humans. Overall, Kevetrin represents a promising avenue for targeted cancer therapy, particularly in tumors with dysfunctional p53 pathways.

Kevetrin

500863-50-3: Kevetrin, with the CAS number 500863-50-3, is a small molecule compound that has garnered attention in the field of cancer research. It is primarily known for its potential as an anti-cancer agent, particularly due to its ability to activate the p53 tumor suppressor pathway. The p53 protein plays a crucial role in regulating the cell cycle and preventing tumor formation, making Kevetrin a candidate for therapeutic applications in various malignancies. The compound is characterized by its unique chemical structure, which facilitates its interaction with cellular mechanisms involved in tumor suppression. In preclinical studies, Kevetrin has demonstrated the ability to induce apoptosis in cancer cells and inhibit tumor growth, highlighting its potential efficacy. Additionally, its pharmacological profile suggests a favorable safety margin, although further clinical trials are necessary to fully establish its therapeutic potential and safety in humans. Overall, Kevetrin represents a promising avenue for targeted cancer therapy, particularly in tumors with dysfunctional p53 pathways.

<p>Applications 4-Isothioureidobutyronitrile-13C2, 15N3 Hydrochloride acts as a reagent in the synthesis of nitrile derivatives and their pharmaceutical uses and compositions.<br>References Menon, K., et al.: PCT Int. Appl. (2010), WO 2010135170 A2 20101125<br></p>

CAS 500863-50-3

Kevetrin

4-Isothioureidobutyronitrile-13C2, 15N3 Hydrochloride

Ref: TR-I917507